Serina Therapeutics, Inc. — Form 8-K Summary
Reporting date: October 5, 2026. The report was signed on October 9, 2026. The filing concerns a corporate charter action, not quarterly or annual financial results.
Business and financial context
Serina Therapeutics filed a Certificate of Elimination with Delaware on October 5, 2026, removing the provisions for its Series A Convertible Preferred Stock from its certificate of incorporation. The filing provides no revenue, earnings, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material change
- The company reports that all issued and outstanding Series A Preferred Stock had been converted into common stock; none remained outstanding, and no further shares would be issued under the Series A designation.
- After the filing, shares previously designated as Series A became authorized but unissued preferred shares with no series designation.
Outlook, risks, and contingencies
The 8-K provides no guidance, outlook, management commentary, or discussion of risks or contingencies related to the action.
Key facts for investors to verify
- Review Exhibit 3.1, the full Certificate of Elimination, for the precise charter changes.
- Confirm the conversion of all Series A Preferred Stock and the resulting common-stock share count using the company’s other relevant filings; this 8-K does not state the number of shares converted.